People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elucida Oncology, Inc. | — | Biotechnology | Series B | $117.1M | $255.6M | 2017 |
Sigurdur A. Olafsson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sigurdur A. Olafsson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Smith | 1 | 20 |
| Isaac Blech | 1 | 14 |
| Robert Ruffolo | 1 | 8 |
| Michael T. Smith | 1 | 5 |
| Tim Boris | 1 | 3 |
| Gary Sender | 1 | 3 |
| Isaac A. Blech | 1 | 3 |
| Robert Essner | 1 | 3 |
| Tim A. Boris | 1 | 2 |
| Teresa Ressel | 1 | 1 |
| Robert A. Ruffolo | 1 | 1 |
| Teresa M. Ressel | 1 | 1 |
| Ulrich T. Wiesner | 1 | 1 |
| Robert A. Essner | 1 | 1 |
| Steven Larson | 1 | 1 |
| Edward Rosen | 1 | 1 |
| Michelle A. Bradbury | 1 | 1 |
| David Zacardelli | 1 | 1 |
| Ulrich Wiesner | 1 | 1 |
| Natalie MacDonald | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.